NRXP earnings: next report 2026-08-17, real EPS beat/miss history, analyst consensus Buy, P/E -3.49. Updated 2026-07-23.
NRx Pharmaceuticals (NRXP) Research Hub
NRx Pharmaceuticals (NRXP) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 3.4 USD (+0.89%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -3.49, market cap 0.08B. This hub links to the full technical, earnings and options research available for NRXP.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 3.4 USD (+0.89%) |
| 52-week range | 2.82 USD – 4.64 USD |
| Trend regime | Range |
| 14-day RSI | 43.6 (Bearish) |
| Trailing P/E | -3.49 |
| Market cap | 0.08B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-17 |
Available research for NRXP
Covered Call on NRXP: how it works, illustrative setup around the real 3.4 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on NRXP: how it works, illustrative setup around the real 3.4 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on NRXP: how it works, illustrative setup around the real 3.4 USD price, max profit/loss, breakeven and when to use it. Educational.
NRXP technical analysis: range, last 3.4 USD, RSI 43.6, 52w range 2.82 USD–4.64 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is NRXP in?
NRx Pharmaceuticals (NRXP) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is NRXP in an uptrend or downtrend?
As of 2026-09-11, NRXP is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is NRXP's trailing P/E ratio?
NRXP's trailing P/E is -3.49, with a market cap of 0.08B. See the earnings research page for full valuation detail.
When does NRXP next report earnings?
NRXP is next scheduled to report earnings on 2026-08-17, with a consensus EPS estimate of -0.09 USD.